Barrier Therapeutics introduces Xolegel CorePak for seborrheic dermatitis

The two products in Xolegel CorePak are new Xebcort gel, a 1% hydrocortisone gel, and Xolegel (ketoconazole, USP) gel, 2%. Xebcort gel provides quick symptom relief and is presented as a 0.8 ounce tube designed for short term use to relieve itch.

Xolegel CorePak contains 45gm of Xolegel gel provided in three 15g tubes. In a long-term safety trial with Xolegel Gel, patients remained symptom free for up to eight weeks post-treatment.

Al Altomari, CEO of Barrier Therapeutics, said: “By providing the hydrocortisone and ketoconazole gels separately in one prescription, Xolegel CorePak encourages patients to comply with their physician’s recommendations to better manage this chronic and common inflammatory skin condition.”